CSPAN Washington This Week August 14, 2016
To support a collaboration with emergent bio solutions, and we are negotiating with several other countries right now for companies right now for their zika vaccine candidates. Because of the limited funds we have available, it is very difficult for us to build a strong portfolio of candidates with industry, to take those to the clinical stage and move them through the pipeline. We are fortunate for the reprogrammed funds, as has been mentioned for ebola, for example, to be able to put some vacc...
Source: archive.org